Revolution's RAS inhibitor may be approved in an all-comer population, but molecular profiling remains key to treatment ...
The firm said it will stop enrolling a late-stage trial in blood cancers to prioritize a preclinical in vivo T-cell receptor program in solid tumors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results